Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer
about
Cost-utility analyses of drug therapies in breast cancer: a systematic review.SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancerPalbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
P2860
Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-Effectiveness of Lapatini ...... itive Metastatic Breast Cancer
@en
Cost-Effectiveness of Lapatini ...... tive Metastatic Breast Cancer.
@nl
type
label
Cost-Effectiveness of Lapatini ...... itive Metastatic Breast Cancer
@en
Cost-Effectiveness of Lapatini ...... tive Metastatic Breast Cancer.
@nl
prefLabel
Cost-Effectiveness of Lapatini ...... itive Metastatic Breast Cancer
@en
Cost-Effectiveness of Lapatini ...... tive Metastatic Breast Cancer.
@nl
P2093
P2860
P356
P1433
P1476
Cost-Effectiveness of Lapatini ...... itive Metastatic Breast Cancer
@en
P2093
Carol Hawkes
Konstantinos Lykopoulos
Mayur M Amonkar
Stephen R D Johnston
Thomas E Delea
P2860
P304
P356
10.1159/000357316
P577
2013-12-01T00:00:00Z